Loading clinical trials...
Loading clinical trials...
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Conditions
Interventions
mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL)
Fludarabine
+6 more
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
November 14, 2025
Primary Completion Date
November 1, 2030
Completion Date
October 1, 2034
Last Updated
January 23, 2026
NCT06823167
NCT05011422
NCT07285668
NCT07195916
NCT07185503
NCT07113925
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions